君圣泰医药-B（02511）今日盘中大跌5.88%，引发市场关注。这一股价下跌紧随公司发布2024年度业绩报告之后。
根据公司公告，截至2024年12月31日止年度，君圣泰医药-B录得股东应占亏损3.82亿元人民币，同比收窄59.35%。尽管亏损幅度有所减少，但公司仍未能实现盈利。每股基本亏损为0.84元人民币。值得注意的是，公司其他收入同比大幅增加98.66%至6797.1万元人民币，主要得益于政府补助增加约2850万元。
虽然君圣泰医药-B的亏损状况有所改善，但投资者似乎对公司仍未能扭亏为盈表示失望。市场反应显示，投资者可能对公司的盈利前景持谨慎态度，导致股价在财报公布后出现明显下跌。未来君圣泰医药-B能否进一步改善经营状况，将继续受到市场密切关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.